Key Decisions in HIV Care: Considering Novel Therapies for HIV

In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss novel therapies for HIV prevention and treatment, including: 

• Prevention
  • Cabotegravir for pre-exposure prophylaxis (PrEP) with the latest results from the HPTN 083 and HPTN 084 studies
  • Novel PrEP therapies in development, including islatravir and lenacapavir
• Initial therapy
  • Lenacapavir for initial therapy with results from the CALIBRATE study
• Switch strategies
  • Cabotegravir as a switch strategy with the latest results from the ATLAS-2M study, evaluating Q4W vs Q8W dosing, data on direct-to-inject without the oral lead-in, and data to date in pregnancy
• Heavily treatment–experienced patients
  • Currently available novel therapies for heavily treatment–experienced patients, including fostemsavir and ibalizumab
  • Lenacapavir for heavily treatment–experienced patients with results from the CAPELLA study

Presenters:

Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Reggio Emilia, Italy 

William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania 

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with the slides at:
https://bit.ly/3vWhjHj

Link to full program:
https://bit.ly/3fOl0XX

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.